Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review

Ling Peng1,2†, Qi-Qi Mao3†, Bo Jiang4, Jin Zhang5, Yi-Lei Zhao6, Xiao-Dong Teng7, Jin-Song Yang1, Yang Xia8, Shi-Qing Chen9, Justin Stebbing10 and Hai Jiang3*

†These authors have contributed equally to this work

1 Department of Radiotherapy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, 2 Department of Respiratory Disease, Zhejiang Provincial People’s Hospital, Hangzhou, China, 3 Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, 4 Department of Ophthalmology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, 5 Department of Urology, Renji Hospital, Shanghai, China, 6 Department of Radiology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, 7 Department of Pathology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, 8 Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, 9 The Medical Department, 3D Medicines Inc., Shanghai, China, 10 Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, United Kingdom

Immune checkpoint inhibitors (ICIs) cause fewer toxicities than conventional chemotherapy. Although most of the immune-related adverse events (irAEs) are mild, reversible, and manageable, potentially severe and rare irAEs remain relevant. We present a 24-year-old man with advanced hereditary renal cancer who developed bilateral posterior uveitis and retinal detachment after systematic treatment of ICI and an anti-angiogenic drug. Axitinib and pembrolizumab were administered with a partial response and following the severe ocular irAE and systemic corticosteroid treatment was initiated. Our case indicates that ocular irAEs may occur rapidly. To the best of our knowledge, this is the first case of posterior uveitis and retinal detachment in hereditary renal cancer patients treated with ICI and anti-angiogenic drugs.

Keywords: retinal detachment, immune checkpoint inhibitor, pembrolizumab, immunotherapy, anti-angiogenesis

INTRODUCTION

Currently, seven ICIs have received FDA approval, targeting CTLA-4 (cytotoxic T-lymphocyte antigen 4), PD-1 (programmed death-1), or PD-L1 (programmed death ligand-1) (1–7), changing the paradigm of cancer treatment by shifting from targeting cancer itself to modulating immune cells in the tumor environment. Nivolumab, a PD-1 inhibitor, improves OS (overall survival) for patients with advanced renal cell carcinoma (RCC) following previous anti-angiogenic therapy as per data from CheckMate-025 (8). At present, pembrolizumab in combination with axitinib was administered with a partial response and following the severe ocular irAE and systemic corticosteroid treatment was initiated. Our case indicates that ocular irAEs may occur rapidly. To the best of our knowledge, this is the first case of posterior uveitis and retinal detachment in hereditary renal cancer patients treated with ICI and anti-angiogenic drugs.
manageable, but irAEs may sometimes lead to treatment discontinuation or withdrawal, and rarely death (14). The overall incidence of irAEs range widely with hepatic toxicities including elevated liver enzymes (35%), endocrine toxicities such as hyperthyroidism or hypothyroidism (28%), hypophysitis (7%), and pneumonitis (7%). The mechanism of irAEs is thought due to auto-reactive T and B cells escape deletion by central tolerance (15). irAEs may also be caused by epitope spreading, which contributes to cross reactivity of self and tumor antigens (16). No prospective trials have determined strategies for managing specific irAE; therefore, clinical practice is variable.

**CASE DESCRIPTION**

A 24-year-old male patient complained of abdominal pain in August 2018. Abdominal computed tomography (CT) and magnetic resonance imaging (MRI) scan detected a mass in his left kidney, with Mayo level IV inferior vena cava tumor thrombus (Figure 1). He had no family history and a radical nephrectomy and inferior vena cava thrombectomy were performed in September 2018. Intraoperative examination found the tumor extended to the right atrium and invaded the wall of the vena cava. A grayish-yellow mass with 11 cm × 7 cm in size with papillary arrangement, irregular nucleus, and large nucleoli and renal venous tumor thrombus formation was identified (Figure 1). Resection margins were negative, and 8 lymph nodes around the renal pedicle were negative. Histology showed was high-grade RCC, papillary type with vena cava tumor thrombus (Supplementary Figure 1). Immunohistology chemistry (IHC) staining indicated CK(pan)(+), p63(−), Napsin A(−), PAX-8(+), Vimentin (+), CK7(−), CD10(+), E-cadherin(+), CD117(−), P504S(+), TFE3(−). Pathological staging was pT3cN0M0, stage III.

Genomic profiling of DNA extracted from tumor specimen and peripheral white cell was performed through next-generation sequencing (NGS). NGS results revealed that TMB (tumor mutation burden) value was 4.03 mutants/Mb and the microsatellite state was stable. IHC indicated that PD-L1 Tumor Proportion Score (TPS) was 25% (Supplementary Figure 1).

Germline mutations of his peripheral blood revealed one FH (Fumarate hydratase) gene germline mutation p.G346Vfs*11 was identified, which has been confirmed as a pathogenic mutation. His tumor sections were stained with anti-FH and anti-2-succinocysteine (2SC) antibodies to confirm the diagnosis (Supplementary Figure 1). His final diagnosis was hereditary leiomyomatosis and renal cell cancer (HLRCC), an unusual and highly aggressive form of renal carcinoma. Furthermore, a CYP2C19 p.P227P mutation was detected, which is reported to contribute to a minor (10%) pathway of axitinib metabolism (17).

Sunitinib (50-mg QD orally) was used as an adjuvant treatment after surgery. Abdominal enhanced CT in May 2019 suggested metastatic lesions in the liver and right adrenal gland (Figure 3). Axitinib (5-mg BID orally) was used as first-line treatment. Response evaluation by B-ultrasound after 1 month confirmed progression of disease (Supplementary Figure 2). Based on the results of KEYNOTE-426 which demonstrated axitinib in combination with pembrolizumab conferred a survival benefit for patients with advanced RCC in the first line setting (18), subsequent treatment with this was given from June 2019 but dosing of pembrolizumab was 100 mg every 3 weeks due to economic considerations. Response evaluation after one dose of pembrolizumab showed a partial response, with shrinkage of hepatic and right adrenal lesions, and response persisted for 5 months (Supplementary Figure 1). However, the patient developed vision deterioration within 3 weeks of the first dose of pembrolizumab, but he did not inform the doctor. In January 2020, his vision deteriorated quickly, and he was referred to an ophthalmologist.

A slit-lamp examination revealed no kerato-precipitates. Tyndall effect was observed and anterior chamber (AC) cells were not obvious in both eyes. His best corrected visual acuity (BCVA) was 0.4 in the both eyes. The intraocular pressure was 13 mmHg in the right eye and 11 mmHg in the left eye. Dilated fundus examination indicated vitreous floaters were not obvious. Large areas of depigmentation were observed in retina, and local

---

**FIGURE 1** | Enhanced CT (A–C) and MRI (D–F) imaging. Significant abnormal findings of left kidney and tumor thrombus of vena cava were noted (arrow).
pigmentation were noticed (Figure 2). Posterior and inferior retinal detachment was observed. Ultrasound examination detected minimal echogenicity in the vitreous and posterior and inferior retinal detachment. Fluorescein (FFA) angiography showed dotted hyperfluorescence in early phase and a little leakage in the maculae. Optical coherence tomography (OCT) revealed neuroepithelial detachment with spotty to patchy high signal, and the choroid is thickened significantly.

The diagnosis was posterior uveitis with bilateral retinal detachment. Immune-related tests and infection-related tests were also performed to rule out uveitis caused by infection or tumor metastasis. The complete blood count (CBC) results were normal and his erythrocyte sedimentation rate (ESR) was increased. Serologic investigations revealed negative for bacterial infection, rheumatoid factor, and tuberculosis. Serum cytokine release was tested, including IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ, and IL-17A. Among these, IL-6 and IL-17A were increased (Table 1). From the time of occurrence, the ocular adverse events may due to immune checkpoint inhibitor. Based on the CTCAE (Common Terminology Criteria for Adverse Events; version 5.0), his ocular irAE was categorized as grade 3. He was treated with intravenous methylprednisolone 60 mg (1 mg/kg) systematically, followed by oral methylprednisolone. Treatment with topical prednisolone acetate (1%) every 2 h was initiated in the both eyes. Follow-ups of OCT is shown in

| Item | Result | Reference range | Unit |
|------|--------|-----------------|------|
| IL-2 | 3.12   | 0.10–4.10       | pg/ml|
| IL-4 | 0.93   | 0.10–3.20       | pg/ml|
| IL-6 | 3.21†  | 0.10–2.90       | pg/ml|
| IL-10| 2.14   | 0.10–5.00       | pg/ml|
| TNF-α| 2.88   | 0.10–23.00      | pg/ml|
| IFN-γ| 4.55   | 0.10–18.00      | pg/ml|
| IL-17A| 4.46†  | 0.10–2.90       | pg/ml|
| CRP  | 0.6    | 0–8.0           | mg/L |
| ESR  | 23     | 0–15.0          | mm/hour|

*IL, interleukin; TNF, tumor necrosis factor; IFN, interferon; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.*

**Figure 3.** Eye MRI at January 2020 also confirmed a thickening of posterior walls (Figure 3). His endocrine results indicated hypothyroidism, which was considered as an irAE, and levothyroxine tablets were commenced.

Our multidisciplinary team decided to permanently discontinue his use of pembrolizumab. At follow-up in February 2020, progressive disease in his adrenal, hepatic and bones were observed (Supplementary Figure 3). There was no indication of metastatic lesions in his eyes. Third-line systemic therapy of bevacizumab and erlotinib was initiated, and the
patient responded well to the combination therapy. The timeline of his diagnosis, treatment and onset of irAE were shown in Supplementary Figure 4.

DISCUSSION

Ocular adverse events are rare, occurring in less than 1% of patients treated with ICIs (19). A systematic review and meta-analysis of ocular toxicities due to ICIs reported that the most common ocular toxicities included uveitis and dry eyes. Pooled analysis for OR (odds ratio) of all-grade immune-related ocular toxicities is 3.40 (95% CI: 1.32–8.71) (20). Due to the inherent characteristics of cohort studies, the prevalence of rare AEs such as ocular toxicities is somewhat underestimated, so the real incidence might be higher than expected (21). A disproportionality analysis of U.S. Food and Drug Administration (FDA) database FAERS demonstrated the reported odds ratios (RORs) of ICIs. Among approved ICIs, nivolumab ranks the highest of ocular adverse events associated with ICI (ROR = 10.54, 95% CI 7.30-15.22) (22).

The precise causal relationship in the scenario of combination therapy is difficult to make a decisive conclusion. As previously reported, targeted therapy and other anti-cancer drugs may also cause ocular toxicities (23). The association of oral anti-VEGF drugs with retinal detachments, while rare, is plausible. But the association of oral anti-VEGF drugs with post uveitis and retinal detachment are unclassified although this suggests a “signal” requiring further study (24). Currently, various anti-angiogenic drugs, such as anti-VEGF antibody (ranibizumab), VEGF trap ( aflibercept), and multikinase tyrosine kinase inhibitor (axitinib) are currently used to treat corneal neovascularization. Sunitinib
malate at the concentration of 12.5 mg/ml caused no toxicity, but 25 mg/ml caused retinal changes suggesting toxicity in the in vivo model (25). There is only an observational case report of impaired retinal circulation of axitinib in treating patient with RCC (26).

We searched FAERS database of spontaneous reports of uveitis and retinal detachment of ICIs using web search tool (https://www.pharmapendium.com/home), using the generic drug name “atezolizumab, avelumab, cemiplimab, durvalumab, ipilimumab, nivolumab, and pembrolizumab”, AND “uveitis”, AND “retinal detachment” up to February 20, 2020. A total of 184 uveitis following ICIs were reported in the database, among which eight cases with uveitis and retinal detachment were identified, including five patients who received nivolumab and three patients with pembrolizumab. We also searched reported cases with sunitinib and axitinib, and there were no cases of uveitis with retinal detachment. The onset time of vision change occurs 3 weeks after initiation of pembrolizumab in this patient, therefore, we suspected the ocular toxicity of this patient were primarily due to pembrolizumab. A retrospective study reported the average onset time of ocular immune-related adverse events (irAEs) from initiation of ICI measured 15.7 weeks (27), but cases also reported ocular irAE onset within 20 days of ICI use (28, 29).

We also searched published literature regarding ICI-related retinal detachment, identifying nine cases with retinal detachment in patient receiving ICIs (Table 2) (30–38). Among them, most of the cases reported were anti-CTLA-4 antibodies. Anti-CTLA-4 agents have a higher function by enhancing T-cell priming, while blockade of PD-1/L1 pathway resulting in re-invigorating CD8 T-cell responses (39). IrAEs are more common in patients treated with CTLA-4 blockades than PD-1/L1 inhibitors, reflecting their different roles in immune regulation (40).

Timely detection of ocular symptoms and subsequent treatment are vital to the outcome of irAEs. Most of the symptoms are not typical, and are easily confounded by underlying co-morbidities, so mild manifestations of ocular toxicities are commonly overlooked. For example, visual deterioration may have different etiologies such as myopia and cataract, etc. Differentiating ocular irAE from other causes has important implications for optimal treatment, including infection, tumor metastasis to eye, and other possible reasons. Patients complaining of eye symptoms while receiving ICI should be seen by an ophthalmologist (21). Therefore, as the occurrence of ocular toxicities, other causes must always be ruled out. A high level of suspicion is needed to monitor and treat ocular toxicities, while in real-world setting, great variation exists. Apart from hypothyroidism and few other possible etiologies during ICI treatment, agreement among observers was poor (41).

In order to rule out the possibility of cancer-related retinopathy, infection and tumor metastasis, observation of ocular findings using multiple imaging analysis can provide insights into possible etiology of the condition. Whole-body PET/CT can be useful for clinical evaluation of patients with uveal metastases (42). The eyes are considered as an immune privileged site, but ocular irAEs can involve any component of the ocular apparatus (43). Patients experiencing ocular adverse events (AEs) may present with any of the following symptoms: blurred/distorted vision, blind spots, decrease in color vision, photophobia, tenderness/pain, eyelid swelling, and proptosis. The most common adverse effects include dry eyes, conjunctivitis, uveitis, and myasthenia gravis (19). Referring to an ophthalmologist is suggested if the symptoms occur. It is recommended that patients should receive ophthalmology examination including visual acuity in each eye, color vision, pupil size, shape, and reactivity, red reflex, and fundoscopic examination (44). During evaluation of vision, sight-threatening effects are ocular myasthenia, corneal punctate epithelial erosions, subconjunctival hemorrhage, corneal perforation, uveitis, hypotony maculopathy, cystoid macular edema, and serous retinal detachment (45). Here, the irAE involves bilateral posterior and retina. Certain parts of the eye are unable to regenerate after destructive inflammation, such as neural retina (46).

There are several guidelines regarding the management of irAEs, including those published by ESMO, SITC, and ASCO/NCCN (47–49). However, the treatment of rare irAEs such as ocular toxicity is not fully clear due to lack of adequate evidence (50). NCCN guidelines recommend the use of systemic corticosteroids and topical steroids as initial treatment (47). If the ocular irAE is grade 1–2, it is possible to continue prior ICI balancing the risk/benefit ratio for each individual patient. The time to resolution of irAEs depends on different organs involved.
(51). In our case report, this patient received steroids for more than a month, while his vision remained stable. In response to the acute inflammatory phase, many cytokines are continuously secreted, notably IL (interleukin)-1, IL-6, and human tumor necrosis factor α (TNFα). An assessment of baseline cytokine level assessment before ICI therapy followed by repeated measurements in case of irAE might be useful.

There are some other issues that require addressing. Firstly, the irAEs in different underlying malignancies may also vary. A systemic review compared the likelihood of irAEs in different tumor types, including RCC, melanoma, and non-small cell carcinoma (NSCLC) (52). HLRCC is a type of familial renal cancers which is driven by FH gene mutation, which is the most aggressive tumor among the familial renal cancer syndromes (53). Most of HLRCCs do not express PD-L1 (54), while in our case the expression of PD-L1 of tumor cell was 25%. There were not enough evidences to support whether this special subtype of RCC would have any link to this rare irAE.

Secondly, combinations of ICI with other drugs such as ICI, chemotherapy or anti-angiogenic drug may lead to higher incidences of irAEs (55, 56). Combination therapy with PD-1 inhibitors and chemotherapy have similar side effects to those of chemotherapy alone; however, combination therapy with CTLA-4 and PD-1 inhibitors may lead to more severe AEs than those with monotherapy (57).

Thirdly, the addition of ICI on the basis of axitinib has led to shrinkage of his hepatic and right adrenal metastatic lesions, while he developed serious ocular toxicities. Literature suggests irAE onset is predictive of anti-PD-(L)1 antibody response across a variety of solid tumors (58–60). However, the relationship of efficacy and toxicity in the ICI evokes debate regarding the “survivor bias” phenomenon (61).

In conclusion, this is the first report of posterior uveitis and retinal detachment with severe vision deterioration in a HLRCC patient receiving ICI and anti-angiogenic drug. The use of ICIs in medical oncology continues to rise significantly; therefore, the number of patients with rare irAEs will increase. There is a need for routinely querying patients during their treatment regarding the occurrence of unexpected adverse events. This case highlights the monitoring and timely detection of rare irAEs in RCC patients receiving ICIs.

**ETHICS STATEMENT**

The patient provided his written consent for the publication of images or data included in this article.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct, and intellectual contribution to the work, and approved it for publication.

**FUNDING**

This study was partially supported by Natural Science Foundation of Zhejiang Province, China (Grant number: LY19H160041).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.549168/full#supplementary-material

**SUPPLEMENTARY FIGURE 1** | Histological and genetic assessment of tumor. (a) Histopathologic findings of renal papillary carcinoma (Hematoxylin and Eosin, 100×). Large atypical cells with marked nucleus proliferate diffusely. (b) PD-L1 staining of the specimen (100×). (c) IHC confirmed loss of staining for FH (100×). (d) Positive staining of 2-succinocysteine (100×). (e) TMB value was 4.03 mutants/Mb. (f) Microsatellite state was stable.

**SUPPLEMENTARY FIGURE 2** | Radiologic mages of tumor evaluation. (a) Hepatic metastatic lesion of CT scan on May 2019 (arrow). (b) Right adrenal metastatic lesion of CT scan on May 2019 (arrow). (c, d) Ultrasound confirmed hepatic and right adrenal lesions on June 2019 (arrow). (e, f) Abdominal MRI indicated shrinkage of hepatic lesion and right adrenal metastasis (arrow) on July 2019. (g, h) Abdominal MRI indicated remission of right adrenal metastasis on November 2019 (arrow).

**SUPPLEMENTARY FIGURE 3** | A positron emission tomography/computed tomography scan identified increased fluorodeoxyglucose uptake in the (a) liver, (b) right adrenal gland, (c, d) nerve roots and (e, f) vertebrae (arrow).

**SUPPLEMENTARY FIGURE 4** | Clinical course of the patient.

**REFERENCES**

1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363(8):711–23. doi: 10.1056/NEJMoa1003466
2. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab in previously treated advanced non-small-cell lung cancer: a多-centre, open-label, phase 2 trial. Lancet (2015) 375(9726):2020–9. doi: 10.1016/S0140-6736(15)00561-4

5. Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol (2016) 17(10):1374–85. doi: 10.1016/S1470-2045(16)30364-3
6. Powles T, Huddart RA, Elliott T, Sarker SJ, Ackerman C, Jones R, et al. Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer. J Clin Oncol (2017) 35(1):48–55. doi: 10.1200/JCO.2015.66.3468
7. Migden MR, Rischin D, Schmitz CD, Guminski A, Hauchild A, Lewis KD, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med (2018) 379(4):341–51. doi: 10.1056/NEJMoa1805131
8. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 373(19):1803–13. doi: 10.1056/NEJMoa1510665
9. Flippot R, Escudier B, Albigeis L. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma. Drugs (2018) 78(14):1443–57. doi: 10.1007/s40265-018-09870-y

10. Albigeis L, Powles T, Staecker M, Bansalal K, Giles RH, Hora M, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. Eur Urol (2019) 76(2):151–6. doi: 10.1016/j.eururo.2019.05.022

11. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 39(1):1–10. doi: 10.1016/j.immuni.2013.07.012

12. Postow MA, Sondel RP, Hodi FS. Immune-related toxicity with immune checkpoint inhibition. Nat Rev Clin Oncol (2018) 15(8):469–70. doi: 10.1038/s41571-018-0064-6

13. Crews J, Agarwal A, Jack L, Xu D, Do DV, Nguyen QD. Ipilimumab-Associated Retinal Toxicity (2017) 32(3):161–8. doi: 10.1089/jop.2018.0019

14. Dambrosio AL, Hurst MG, Luton DR, Blumenstein BA. Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med (2017) 23(5):540–7. doi: 10.1038/nm.4321

15. Zientek MA, Goosen TC, Tseng E, Lin I, Jauneman JN, Walker GS, et al. In Vitro Kinetic Characterization of Axitinib Metabolism. Drug Metab Dispos (2016) 44(1):102–14. doi: 10.1124/dmd.0056515

16. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal Cell Carcinoma. N Engl J Med (2019) 380(12):1116–27. doi: 10.1056/NEJMoa1816714

17. Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint Inhibitor Immune Therapy: Systemic Indications and Ophthalmic Side Effects. Retina (2018) 38(6):1063–79. doi: 10.1097/IAE.0000000000002181

18. Abdel-Rahman O, Oweira H, Petrausch U, Helbling D, Schmidt J, Mannhart M, et al. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Anticancer Ther (2017) 17(4):387–94. doi: 10.1080/14737140.2017.1296765

19. Bitton K, Michot JM, Barreau E, Lambotte O, Haigh O, Marabelle A, et al. Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy. Am J Ophthalmol (2019) 202:109–17. doi: 10.1016/j.ajo.2019.02.012

20. Fang T, Maberley DA, Elminar M, Ocular adverse events with immune checkpoint inhibitors. J Cancr Res Treat (2019) 31(3):319–22. doi: 10.1186/s12871-019-0505-2

21. Ho WL, Wong H, Yau T. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta Ophthalmol (2013) 91(7):604–9. doi: 10.1111/j.1756-185X.2012.02518.x

22. Fraunfelder FT, Fraunfelder FW. Oral Anti-Vascular Endothelial Growth Factor Drugs and Ocular Adverse Events. J Ocul Pharmacol Ther (2018) 34(6):432–5. doi: 10.1089/jop.2018.0019

23. Dib E, Maia M, Lima Ade S, de Paula Fiord Costa E, de Moraes-Filho MN, Rodrigues EB, et al. In vivo, in vitro toxicity and in vitro angiogenic inhibition of sunitinib malate. Curr Eye Res (2012) 37(7):567–74. doi: 10.3109/02716831.2011.635916

24. Kimura M, Kusuhara S, Tagami M, Nakamura M. Impaired Retinal Circulation during Axitinib Treatment for Metastatic Renal Cell Carcinoma. Case Rep Ophthalmol (2019) 10(1):5–10. doi: 10.1159/000496197

25. Noble CW, Gangapurta SS, Thompson IA, Yuan A, Apolob AB, Lee JM, et al. Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies. Ocul Immunol Inflamm (2020) 28(6):585–9. doi: 10.1080/09273948.2019.1583347

26. Sengd Samanai N, Ozan T, Celik E, Demirelli FH. Optic Neuritis Related to Antiangiogenesis Treatment in a Patient With Metastatic Non-Small-Cell Lung Cancer. JCO Oncol Pract (2020) 16(2):96–8. doi: 10.1200/JOP.19.00483

27. Emens LA, Davis SL, Oliver SCN, Lieu CH, Reddy A, Solomon S, et al. Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis. JAMA Ophthalmol (2019) 137(1):96–100. doi: 10.1001/jamaophthalmol.2018.5191

28. Miyakado T, Mukai R, Nakamura K, Matsumoto H, Akiyama H. A Case Of Ophthalmomuscarinic-Induced Unusual Severe Retinal Detachment In Bilateral Eyes. Int Med Case Rep J (2019) 12:355–61. doi: 10.2147/IMCRJ.S225173

29. Wang W, Lam WC, Chen L. Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma. Cancer Immunol Immunother (2019) 68(1):85–95. doi: 10.1007/s00262-018-2260-7

30. Rapisuwon S, Izar B, Batetchuk C, Avila A, Mei S, Sorger P, et al. Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors. J Immunother Cancer (2019) 7(1):61. doi: 10.1186/s40425-019-0533-0

31. Obata S, Saishin Y, Teramura K, Ohji M. Vogt-Koyanagi-Hara disease-like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma. Case Rep Ophthalmol (2019) 10(1):67–74. doi: 10.1007/s40496-018-0079-5

32. Telfah M, Whittaker TJ, G. CD Vision loss with pembrolizumab treatment: A report of two cases. J Oncol Pract (2019) 25(6):1540–6. doi: 10.1177/1078155219841683

33. Tsui E, Madu A, Belinsky I, Yannuzzi LA, Freund KB, Modi YS. Combination Ipilimumab and Nivolumab for Metastatic Melanoma Associated With Ciliary Body Uveitis. Ophthalmology (2019) 126(12):1769–76. doi: 10.1016/j.ophtha.2019.06.017

34. Theo-lopolous AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol (2013) 14(12):1721–9. doi: 10.1038/nm.4321

35. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol (2018) 4(12):1721–8. doi: 10.1001/jamaoncology.2018.3923
Toxicity Management Working Group. J Immunother Cancer (2017) 5(1):95. doi: 10.1186/s40425-017-0300-z

49. Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2017) 28 (suppl_4):iv119–42. doi: 10.1093/annonc/mdx225

50. Schoenfeld SR, Aronow ME, Leaf RK, Dougan M, Reynolds KL. Diagnosis and Management of Rare Immune-Related Adverse Events. Oncologist (2020) 25(1):6–14. doi: 10.1634/theoncologist.2019-0083

51. Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grunwald V, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev (2016) 45:7–18. doi: 10.1016/j.ctrv.2016.02.003

52. Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol (2017) 28(10):2377–85. doi: 10.1093/annonc/mdx286

53. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet (2002) 30(4):406–10. doi: 10.1038/ng849

54. Alaghehbandan R, Stehlik J, Trpkov K, Magi-Galluzzi C, Condom Mundo E, Pane Foix M, et al. Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma. Ann Diagn Pathol (2017) 29:17–22. doi: 10.1016/j.anndiagpath.2017.04.007

55. Winer A, Bodor JN, Borghaei H. Identifying and managing the adverse effects of immune checkpoint blockade. J Thorac Dis (2018) 10(Suppl 3):S480–9. doi: 10.21037/jtd.2018.01.111

56. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol (2016) 13(6):473–86. doi: 10.1038/nrclinonc.2016.58

57. Chamoto K, Hatae R, Honjo T. Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int J Clin Oncol (2020) 25(5):790–800. doi: 10.1007/s10147-019-01588-7

58. Fuji T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, et al. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs (2018) 36(4):638–46. doi: 10.1007/s10637-017-0534-0

59. Akamatsu H, Murakami E, Oyanagi I, Shibaki R, Kaki T, Takase E, et al. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer. Oncologist (2020) 25(4):e679-83. doi: 10.1634/theoncologist.2019-0299

60. Das S, Ciombor KK, Haraldsdottir S, Pumplava Y, Sahin IH, Pineda G, et al. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. Oncologist (2020) 25(8):669–79. doi: 10.1634/theoncologist.2019-0637

Conflict of Interest: SQC was employed by the company 3D Medicines Inc. JS is editor-in-chief of Oncogene. JS has sat on a number of scientific advisory boards, including Benevolent AI, and consults with Lansdowne partners and Vitruvian; he sits on the Board of Directors for BB Biotech Healthcare Trust and chairs Xerion Healthcare.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Peng, Mao, Jiang, Zhang, Zhao, Teng, Yang, Xia, Chen, Stebbing and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.